Last reviewed · How we verify
Crenessity (CRINECERFONT)
Crenessity blocks the hormone corticotropin-releasing factor, which stimulates the adrenal glands to produce excess hormones.
At a glance
| Generic name | CRINECERFONT |
|---|---|
| Sponsor | Neurocrine |
| Drug class | Corticotropin-releasing Factor Type 1 Receptor Antagonist [EPC] |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
| First approval | 2024 |
Mechanism of action
Crinecerfont is a selective corticotropin-releasing factor (CRF) type 1 receptor antagonist. Crinecerfont blocks the binding of CRF to CRF type 1 receptors in the pituitary but not CRF type 2 receptors. Crinecerfont binding to CRF type 1 receptors inhibits adrenocorticotropic hormone (ACTH) secretion from the pituitary, thereby reducing ACTH-mediated adrenal androgen production.
Approved indications
- classic congenital adrenal hyperplasia (CAH)
Common side effects
- Neutrophil count less than 2 x 10^3 cells/mcL
- Neutrophil count less than 1 x 10^3 cells/mcL
- Fatigue
- Headache
- Abdominal pain
- Dizziness
- Arthralgia
- Nasal congestion
- Epistaxis
- Myalgia
- Decreased appetite
- Back pain
Drug interactions
- Strong CYP3A4 Inducers
- Moderate CYP3A4 Inducers
- Strong CYP3A4 Inducers
- Moderate CYP3A4 Inducers
- Strong CYP3A4 Inducers
- Moderate CYP3A4 Inducers
- Strong CYP3A4 Inducers
- Moderate CYP3A4 Inducers
- Strong CYP3A4 Inducers
- Moderate CYP3A4 Inducers
Key clinical trials
- Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old (PHASE2)
- Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (PHASE3)
- Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study) (PHASE3)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia (PHASE2)
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Crenessity CI brief — competitive landscape report
- Crenessity updates RSS · CI watch RSS
- Neurocrine portfolio CI